F S&P 500
5,507.50 +16.50 (+0.30%) F Dow Jones
38,863.00 +4.00 (+0.01%) F Nasdaq
20,014.25 +95.00 (+0.48%) E-mini Russell 2000 Index Futur
2,051.30 +2.00 (+0.10%) Petróleo
81.59 +0.02 (+0.02%) Oro
2,351.90 +5.00 (+0.21%)
X4 Pharmaceuticals, Inc. (XFOR)
Antes de la apertura del mercado:
X4 Pharmaceuticals, Inc.
61 North Beacon Street
4th Floor
Boston, MA 02134
United States
857 529 8300
https://www.x4pharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 116
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Paula Ragan Ph.D. | CEO, President & Director | 1.01M | N/D | 1970 |
| Mr. Adam S. Mostafa | CFO, Treasurer & Corporate Secretary | 700.78k | N/D | 1980 |
| Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D. | Chief Medical Officer | 379.8k | N/D | 1962 |
| Dr. Richard Peters M.D., Ph.D. | Founder | N/D | N/D | 1963 |
| Dr. Renato T. Skerlj Ph.D. | Founder | N/D | N/D | N/D |
| Dr. Keith T. Flaherty M.D. | Founder & Member of Corporate Advisory Board | N/D | N/D | 1971 |
| Dr. Mary DiBiase Ph.D. | Chief Operating Officer | 661.59k | N/D | 1961 |
| Dr. Arthur Taveras Ph.D. | Chief Scientific Officer | N/D | N/D | 1964 |
| Dr. Robert David Arbeit | Senior Vice President of Clinical Development and Translational Research | N/D | N/D | 1948 |
| Mr. Mark Baldry M.B.A. | Chief Commercial Officer | N/D | N/D | 1964 |
Descripción
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de X4 Pharmaceuticals, Inc. a partir del 1 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 6; Derechos del accionista: 8; Compensación: 9.
